CD38 and Miyoshi myopathy: Lipoic acid-crosslinked hyaluronic acid nanoparticles loaded with DOX37, a catechol-functionalized polycarbonate core that encapsulates BTZ38, and anti-CD38 antibody–conjugated poly(ethyleneoxide)-block-poly(-benzylcarboxylate-”-caprolactone) (PEO-b-PBCL) NPs loaded with S3I-1757, an inhibitor of STAT330, have been developed as potential therapeutic candidates in the treatment of MM.